Browse by Medical Category
Accepting New Patients
Go To Programs
Note: This provider may accept more insurance plans than shown; please call the practice to find out if your plan is accepted.
Dr. Evins completed her residency in adult psychiatry at the Massachusetts Mental Health Center and Longwood Psychiatry Residency Training Program, where she was Chief Resident. She conducted a fellowship in molecular biology at the Mailman Research Center of McLean Hospital and a second fellowship in clinical research at the Massachusetts GeneralHospital.
Dr. Evins became the Director of the MGH Center for Addiction Medicine and completed a Masters in Public Health with a concentration in Clinical Effectiveness at the Harvard School of Public Health in 2005. She has been an active member of the MGH Schizophrenia and Depression Clinical and Research Program since 1995.
Dr. Evins' research interests include pharmacotherapy for nicotine dependence, negative symptoms of schizophrenia, co-occurring psychiatric and substance use disorders and cognitive dysfunction in schizophrenia. Additionally, she is studying the effects of various medications on reward responsiveness and other potential biomarkers of vulnerability to addiction and of treatment response. She has authored articles, book chapters, and reviews on related topics. Her articles are published in scientific journals, such as American Journal of Psychiatry, Neuropsychopharmacology, Biological Psychiatry, Journal of Clinical Psychopharmacology, and Journal of Neural Transmission.
Dr. Evins has twice received the National Alliance for Research on Schizophrenia and Affective Disorders Young Investigator Award, and has been awarded the New Clinical Drug Evaluation Unit Award for Young Investigators sponsored by the National Institute of Mental Health, the Mass. Dept. of Public Health Young Investigator Award and two career development awards from NIDA.
She is currently supported by six major grants from the National Institutes of Drug Abuse for her work testing novel therapies for nicotine dependence in the general population and in those with co-occuring psychiatric disorders.
The weight gain that can result from quitting smoking does not eliminate the reduction in cardiovascular risks associated with smoking cessation among patients with serious mental illness, at least not during the first year.
Anne Eden Evins, MD, MPH, director of the MGH Center for Addiction Medicine, recently was recognized for her exceptional work in this area as the first incumbent of the William Cox Family Professorship in Psychiatry in the Field of Addiction Medicine Harvard Medical School.
Extended treatment with the smoking cessation drug varenicline significantly improved the ability of individuals with serious mental illness to maintain abstinence from tobacco after a standard 12-week course of treatment.
Back to Top